Skip to main content

Table 1 Pooled estimates of proportions for risk and benefit outcomes in studies evaluating the use of anticoagulant prophylaxis for venous thromboembolism in orthopedic surgery

From: Comparing multiple competing interventions in the absence of randomized trials using clinical risk-benefit analysis

Drug Major Venous Thromboembolism Major Bleeding
  % (95% CI) Variance % (95% CI) Variance
All patients     
Ximelagatran 3.274 (3.175, 3.372) 0.098 1.804 (1.722, 1.885) 0.082
LMWH 6.528 (6.357, 6.699) 0.171 2.208 (2.156, 2.260) 0.052
UFH 13.394 (12.862, 13.926) 0.532 2.494 (2.363, 2.625) 0.131
Warfarin 6.278 (6.092, 6.463) 0.186 1.778 (1.690, 1.867) 0.088
Fondaparinux 2.051 (1.957, 2.146) 0.094 5.113 (4.690, 5.536) 0.423
Placebo 21.019 (19.978, 22.060) 1.041 1.781 (1.651, 1.912) 0.130
Total hip replacement     
Ximelagatran 3.401 (3.181, 3.621) 0.220 2.892 (2.683, 3.101) 0.209
LMWH 6.472 (6.293, 6.651) 0.179 2.151 (2.085, 2.216) 0.066
UFH 15.154 (14.446, 15.862) 0.708 2.813 (2.625, 3.001) 0.188
Warfarin 4.280 (4.083, 4.477) 0.197 2.229 (2.088, 2.371) 0.141
Fondaparinux 2.138 (2.009, 2.267) 0.129 6.033 (5.501, 6.566) 0.532
Placebo 24.726 (23.268, 26.184) 1.458 1.463 (1.299, 1.628) 0.164
Total knee replacement     
Ximelagatran 3.100 (3.042, 3.158) 0.058 1.127 (1.095, 1.159) 0.032
LMWH 5.143 (5.010, 5.277) 0.134 1.605 (1.566, 1.644) 0.039
UFH 9.119 (8.803, 9.436) 0.316 0.943 (0.837, 1.050) 0.106
Warfarin 8.100 (7.879, 8.322) 0.221 0.822 (0.792, 0.852) 0.030
Fondaparinux 2.446 (2.288, 2.603) 0.158 2.128 (2.003, 2.252) 0.124
Placebo 14.833 (14.351, 15.314) 0.482 2.116 (1.911, 2.322) 0.205
  1. VTE Venous thromboembolism; CI Confidence interval; LMWH Low molecular weight heparin; UFH Unfractionated heparin.